Latest News
4D Molecular Therapeutics, Inc.
- H.C. Wainwright reiterates 4D Molecular stock rating at buy By Investing.com
- 4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
- FDMT: 4D-150 targets continuous wet AMD control, with two pivotal readouts expected in 2027
- 4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day - Slideshow (NASDAQ:FDMT) 2026-10-21
- Transcript : 4D Molecular Therapeutics, Inc. - Analyst/Investor Day
- FDMT: PRISM supports 4D-150’s backbone-therapy thesis as global Phase 3 results approach in 2027
- Scott Bizily, 4D Molecular Therapeutics CLO, sells $20,993 in stock
- Form 4 4D Molecular Therapeutics Inc: Scott Bizily (CLO) For: 16 October
- 4D molecular therapeutics CEO David Kirn sells $753k in company stock
- B.Riley reiterates Buy on 4D Molecular stock, cites trial design
- 4D Molecular Therapeutics Insiders Sold US$757k Of Shares Suggesting Hesitancy
- 4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway
Headlines from the last 30 days, linking to the original publishers. See all market news →